This is a working overview of GIP receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-09. Anything still debated is marked as such rather than presented as settled.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Of its hereditary nature. When either or both the parents have shown manifestations of the disease ... one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease. Sir William Osler was interested in the disorder and chorea in general, and was impressed with Huntington's paper, stating, "In the history of medicine, there are few instances in which a disease has been more accurately, more graphically or more briefly described." Osler's continued interest in HD, combined with his influence in the field of medicine, helped to rapidly spread awareness and knowledge of the disorder throughout the medical community. Great interest was shown by scientists in Europe, including Louis Théophile Joseph Landouzy, Désiré-Magloire Bourneville, Camillo Golgi, and Joseph Jules Dejerine, and until the end of the century, much of the research into HD was European in origin. By the end of the 19th century, research and reports on HD had been published in many countries and the disease was recognized as a worldwide condition. During the rediscovery of Mendelian inheritance at the turn of the 20th century, HD was used tentatively as an example of autosomal dominant inheritance. English biologist William Bateson used the pedigrees of affected families to establish that HD had an autosomal dominant inheritance pattern.
== Causes == A spontaneous spinal CSF leak refers to any CSF leak that has not been preceded by a surgical or other medical procedure. Later evidence suggests that these leaks result from either a discogenic pathology, such as microspur, osteophyte or spinal disc herniation that pierces the dura like a knife, connective tissue disorder (which can often lead to discogenic pathology), or spinal drainage problems. A cerebrospinal fluid leak can be a rare complication of an anterior cervical discectomy and fusion. One study suggested a CSF leak to follow from 0.5% of operations. Another study suggests a CSF leak to follow from 1% of operations. In most of these cases repair is successful.
===== Activated carbon ===== Activated carbons (ACs) or biological-activated carbon (BAC) are effective adsorbents for a wide variety of contaminants. The adsorptive removal of color, aroma, taste, and other harmful organics and inorganics from drinking water and wastewater is one of their industrial applications. Both a high surface area and a large pore size can improve the efficiency of activated carbon. Activated carbon was utilized by a number of studies to remove heavy metals and other types of contaminants from wastewater. The cost of activated carbon is rising due to a shortage of commercial activated carbon (AC). Because of its high surface area, porosity, and flexibility, activated carbon has a lot of potential in wastewater treatment.
=== Diplomats === Hamzat Ahmadu - Nigerian diplomat, former ambassador to the Soviet Union, the United States of America and high commissioner to the Bahamas. Nuhu Bamalli - Former minister of foreign affairs Mohammed Sanusi Barkindo – 28th Secretary-General of OPEC. Ibrahim Gambari – (Fulani/Yoruba); Scholar and diplomat; Chief of Staff to the president; Under-Secretary-General / Special Adviser – Africa United Nations; former minister of foreign affairs, current chief of staff to the president of Nigeria. Amina J. Mohammed – (Fulani/English); Politician; Deputy Secretary-General of the United Nations; former Federal Minister of Environment, Nigeria. Tijjani Muhammad-Bande – Political scientist, administrator and career diplomat. Current president of the United Nations General Assembly, Permanent Representative of Nigeria to the UN, former VP of the UN General Assembly. Nura Abba Rimi - Nigeria's ambassador to the Arab Republic of Egypt, with concurrent accreditation to the State of Palestine and the State of Eritrea; former Presidential Liaison Officer. Ibrahim Sulu-Gambari – (Fulani/Yoruba); Nigerian judge and monarch. Current Emir of Ilorin, Nigeria. Yusuf Tuggar – Minister of Foreign Affairs. Aminu Bashir Wali - Former permanent representative to the United Nations, former minister of foreign affairs. Isa Wali - former Nigerian high commissioner to Ghana.
The non-sterile form of Povidone iodine has a long history of intrinsic contamination with Burkholderia cepacia (a.k.a. Pseudomonas cepacia), and other opportunistic pathogens. Its ability to harbor such microbes further underscores the importance of using sterile products in any clinical setting. Since these bacteria are resistant to povidone iodine, statements that bacteria do not develop resistance to PVP-I, should be regarded with great caution: some bacteria are intrinsically resistant to a range of biocides including povidone-iodine.
Sources: en.wikipedia.org
A shipping container is a container with strength suitable to withstand shipment, storage, and handling. Shipping containers range from large reusable steel boxes used for intermodal shipments to the ubiquitous corrugated boxes. In the context of international shipping trade, "container" or "shipping container" is virtually synonymous with intermodal freight container (sometimes informally called a "sea can"), a container designed to be moved from one mode of transport to another without unloading and reloading.
== Replication == Replication of the R1 plasmid begins at the oriRI site on the plasmid. RepA is the plasma-encoded initiator protein that binds to oriRI in order to initiate replication. RepA needs a 188-bp region of DNA at minimum in order to bind. Initiation of the leading strand, primed by DnaG, occurs at a G-type priming signal. This signal is located 400 bp downstream of the RepA-binding sequences. A newly synthesized RepA protein is used by an oriR on the same template that it was synthesized on, a cis-specific action.
== History == Vardenafil was co-marketed by Bayer Pharmaceuticals, GlaxoSmithKline, and Schering-Plough under the brand name Levitra. As of 2005, the co-promotion rights of GSK on Levitra have been returned to Bayer in many markets outside the US. In Italy, Bayer sells vardenafil as Levitra and GSK sells it as Vivanza. Thus, because of European Union trade rules, parallel imports might result in Vivanza sold next to Levitra in the EU. An orally disintegrating form, marketed as Staxyn and Levitra Soft, has been gaining approvals in countries such as the United States and Canada.
This was a controversial measure in Labour strongholds such as East London, Merseyside and North East England. He obtained a Treasury grant of £77 million to build the Docklands Light Railway, although transport links to Docklands remained inadequate. He opened Britain's first Enterprise Zone at Corby in Northamptonshire. Some criticism was made of his time in Liverpool that he spent a lot of money but generated little in the way of new employment ("I would not blame him for that: Liverpool had defeated better men than Michael Heseltine" commented Lady Thatcher acidly in her memoirs in 1993). Local Labour politicians tended to feel that he had accomplished little, although they acknowledged his good intentions. However a more positive assessment was offered by Michael Parkinson, Professor of Urban Affairs at John Moores University: although he had been sceptical in the 1980s, by 1997 he had come to favour the policies championed by Heseltine: assignment of ministers to regions, development of housing associations and cooperatives, and the channelling of government money through business-led agencies rather than through local government.
Sources: en.wikipedia.org
One of the key scientific figures that attempted to highlight the promising aspects of genetic engineering was Joshua Lederberg, a Stanford professor and Nobel laureate. While in the 1960s "genetic engineering" described eugenics and work involving the manipulation of the human genome, Lederberg stressed research that would involve microbes instead. Lederberg emphasized the importance of focusing on curing living people. Lederberg's 1963 paper, "Biological Future of Man" suggested that, while molecular biology might one day make it possible to change the human genotype, "what we have overlooked is euphenics, the engineering of human development." Lederberg constructed the word "euphenics" to emphasize changing the phenotype after conception rather than the genotype which would affect future generations. With the discovery of recombinant DNA by Cohen and Boyer in 1973, the idea that genetic engineering would have major human and societal consequences was born. In July 1974, a group of eminent molecular biologists headed by Paul Berg wrote to Science suggesting that the consequences of this work were so potentially destructive that there should be a pause until its implications had been thought through. This suggestion was explored at a meeting in February 1975 at California's Monterey Peninsula, forever immortalized by the location, Asilomar.
Official website Ellen McLain at IMDb Ellen McLain speaking on YouTube, Anime Midwest 2011 convention The VŌC Podcast // Ellen McLain Interview (The voice of GLaDOS, The Administrator, Overwatch) on YouTube
=== October === 1 October – PPE Medpro is ordered to pay back £122m to the government after supplying non-compliant medical gowns during the COVID-19 pandemic. 2 October – Former Conservative MP Sarah Atherton joins Reform UK and says she wants to stand in the 2026 Senedd election. Reform UK-led Nottinghamshire County Council partially lift the ban they imposed on the Nottingham Post in response to a request to lift it in full from a law firm representing the publishers. Kemi Badenoch pledges to repeal the Climate Change Act 2008. 3 October – Dame Sarah Mullally is named as the first female Archbishop of Canterbury, replacing Justin Welby following his resignation. Zack Polanski makes his keynote speech as leader of the Green Party of England and Wales at their annual conference. Shabana Mahmood calls Pro-Palestinian protests "un-British" following the 2025 Manchester synagogue attack. Michelle Mone, Baroness Mone says she has no wishes to return to the House of Lords. 4 October – The 2025 Conservative Party Conference begins in Manchester. London Assembly member Keith Prince defects from the Conservative Party to Reform UK. 5 October – The Conservatives say they would task officials with deporting 750,000 migrants over five years if they form the next government. 7 October – The Guardian publishes video footage of Robert Jenrick, the Shadow Justice Secretary, describing the Handsworth area of Birmingham as "one of the worst-integrated places" in the UK during an after dinner speech recorded in March. 20 Conservative councillors defect to Reform UK.
== Early life == Morgan was born on November 10, 1968, in Brooklyn and raised in Brooklyn's Marlboro Houses and Tompkins Houses in its Bedford–Stuyvesant neighborhood. He is the second of five children of a homemaker, Alicia (née Warden), and James Morgan Jr IV, a musician who left the family when Morgan was six years old. His father named him Tracy in honor of a platoon mate and friend who shipped off to Vietnam with him and was killed in action days later. The target of bullies as a child, Morgan attended DeWitt Clinton High School in The Bronx. In 1985, during his senior year, he learned that his father had contracted HIV from hypodermic needle use. His father died in January 1987, aged 38. Morgan married his girlfriend Sabina that year and dropped out of high school just four credits short of his diploma to care for his ailing father. Living on welfare, Morgan sold crack cocaine with limited success, but began earning money performing comedy on the streets after his best friend was murdered. He said in 2009: "He would say to me, 'Yo, Tracy, man, you should be doing comedy.' A week later, he was murdered. And that for me, that was like my Vietnam. I had my survival guilt when I started to achieve success. Why I made it out and some guys didn't." Morgan embarked on a stand-up comedy career, successfully enough that he "finally moved to a nice community in [The Bronx neighborhood of] Riverdale, from a run-down apartment next to Yankee Stadium in the Bronx."
=== Drugs === The anti-diabetic medication pioglitazone was shown in a mouse model of ALD to be effective at treating the metabolic effects of ALD, including metabolic failure and increased oxidative stress. Pioglitazone was also shown to prevent axonal degeneration and increase mitochondria levels, as well as stop the progression of locomotor decline in ALD model mice. Subsequently, the experimental drug leriglitazone has been developed as a more brain penetrant metabolite of pioglitazone. As of 2023, leriglitazone is in phase 2/3 clinical trials for adult and childhood cALD in the USA and the EU, and has completed a clinical trial for AMN.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。